ProQR Therapeutics NV Company Profile (NASDAQ:PRQR)

About ProQR Therapeutics NV

ProQR Therapeutics NV logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRQR
  • CUSIP:
Key Metrics:
  • Previous Close: $6.40
  • 50 Day Moving Average: $6.50
  • 200 Day Moving Average: $5.48
  • 52-Week Range: $23,346,000.00 - $3.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.66
  • P/E Growth: 0.00
  • Market Cap: $149.41M
  • Outstanding Shares: 23,346,000
  • Beta: 0.91
  • Return on Equity: -38.78%
  • Return on Assets: -34.32%
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 10.37%
  • Quick Ratio: 10.37%
Additional Links:
Companies Related to ProQR Therapeutics NV:

Analyst Ratings

Consensus Ratings for ProQR Therapeutics NV (NASDAQ:PRQR) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $15.90 (148.44% upside)

Analysts' Ratings History for ProQR Therapeutics NV (NASDAQ:PRQR)
DateFirmActionRatingPrice TargetDetails
10/14/2016Leerink SwannReiterated RatingOutperform$14.00View Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00View Rating Details
9/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/20/2016Chardan CapitalInitiated CoverageNeutral$4.50View Rating Details
1/6/2016HC WainwrightReiterated RatingBuy$40.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/17/2016Q2($0.48)($0.48)ViewN/AView Earnings Details
5/18/2016Q1($0.41)($0.50)ViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
Current Year EPS Consensus Estimate: $-2.09 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by


Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
DateHeadline logoProQR Therapeutics N.V. (PRQR) is Overbought: Is A Drop Coming? (NASDAQ:PRQR) - September 27 at 6:45 PM logoProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC (NASDAQ:PRQR) - September 27 at 11:27 AM logoProQR to Present at Scientific and Investor Conferences in September (NASDAQ:PRQR) - September 6 at 11:39 AM logoProQR Announces Results for the Second Quarter of 2016 (NASDAQ:PRQR) - August 17 at 9:56 AM logoProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis (NASDAQ:PRQR) - July 19 at 7:00 AM logoProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC (NASDAQ:PRQR) - June 21 at 9:19 AM logoCoverage initiated on ProQR Therapeutics by Chardan Capital Markets (NASDAQ:PRQR) - June 20 at 5:50 AM logoProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRQR) - June 8 at 6:03 PM logoProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference (NASDAQ:PRQR) - June 1 at 7:23 AM logoProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation (NASDAQ:PRQR) - June 1 at 7:23 AM logo7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10 (NASDAQ:PRQR) - June 1 at 7:04 AM logoProQR Announces Results for the First Quarter of 2016 (NASDAQ:PRQR) - May 18 at 7:42 AM logoProQR reports 1Q loss (NASDAQ:PRQR) - May 18 at 7:23 AM logoProQR reports 4Q loss (NASDAQ:PRQR) - February 17 at 7:19 AM logoProQR to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:PRQR) - February 3 at 7:00 AM logoWhy ProQR Therapeutics (PRQR) Stock Might be a Great Pick (NASDAQ:PRQR) - December 22 at 8:33 AM logoHedge Funds Aren’t Crazy About ProQR Therapeutics NV (PRQR) Anymore (NASDAQ:PRQR) - December 14 at 9:24 PM logoProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session (NASDAQ:PRQR) - December 9 at 8:45 AM logoPROQR THERAPEUTICS N.V. Financials (NASDAQ:PRQR) - December 8 at 1:09 PM logoProQR Announces R&D Day and Provides Update on Innovation Portfolio (NASDAQ:PRQR) - November 30 at 7:00 AM logoProQR Therapeutics (PRQR) Falls: Stock Goes Down 24.8% (NASDAQ:PRQR) - November 24 at 8:50 AM logoProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials (NASDAQ:PRQR) - November 23 at 7:02 AM logoProQR reports 3Q loss (NASDAQ:PRQR) - November 23 at 6:39 AM logoProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences (NASDAQ:PRQR) - October 1 at 7:18 AM logoProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment (NASDAQ:PRQR) - September 14 at 7:15 AM logoProQR Announces Results for the Second Quarter of 2015 (NASDAQ:PRQR) - August 19 at 8:38 AM logoProQR reports 2Q loss (NASDAQ:PRQR) - August 19 at 8:15 AM


ProQR Therapeutics NV (NASDAQ:PRQR) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff